Gene Therapy Clinical Trial Services Market Report 2026

Gene Therapy Clinical Trial Services Market Overview

• Gene Therapy Clinical Trial Services market size has reached to $1.82 billion in 2025 • Expected to grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 19.1% • Growth Driver: The Increasing Demand For Personalized Medicine Is Fueling The Growth Of The Market Due To Advancements In Genomics And Tailored Therapeutic Approaches • Market Trend: Innovative Decentralized Clinical Trial Platforms Transforming Gene Therapy Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gene Therapy Clinical Trial Services Market?

Gene therapy clinical trial services refer to the specialized support, infrastructure, and expertise provided to design, manage, and conduct clinical trials that evaluate gene therapy products in humans. These services encompass a wide range of activities to ensure that investigational gene therapies are tested safely, ethically, and efficiently, while generating reliable clinical evidence to support regulatory approval and potential commercialization. The main types of gene therapy clinical trial services are clinical trial design and planning, supply and logistics services, regulatory services, data management and biostatistics, site management and monitoring, and others. Clinical trial design and planning is the process of outlining a study’s objectives, methods, timelines, and analysis to ensure it is scientifically valid and compliant with regulations. These services, applied across various applications, include oncology, hematology, endocrine or metabolic disorders, musculoskeletal diseases, cardiovascular diseases, neurology disorders, infectious diseases, ophthalmology, immunology, and others, and cater to several end users such as pharmaceutical companies, biotechnology firms, academic institutions, government research institutes, and contract research organizations.

What Is The Gene Therapy Clinical Trial Services Market Growth Forecast?

The gene therapy clinical trial services market size is expected to see rapid growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to increasing number of late-stage gene therapy trials, rising demand for global trial execution capabilities, expansion of rare disease gene therapy programs, growing use of digital trial management platforms, increasing focus on accelerated regulatory approvals. Major trends in the forecast period include increasing demand for specialized gene therapy trial management, rising adoption of decentralized and hybrid trial models, growing focus on advanced cold chain and logistics support, expansion of patient-centric trial design approaches, enhanced emphasis on regulatory and data integrity services.

Global Gene Therapy Clinical Trial Services Market Segmentation

1) By Type: Clinical Trial Design And Planning, Supply And Logistics Services, Regulatory Services, Data Management And Biostatistics, Site Management And Monitoring, Other Types 2) By Application: Oncology, Hematology, Endocrine or Metabolic Disorders, Musculoskeletal Diseases, Cardiovascular Diseases, Neurology Disorders, Infectious Diseases, Ophthalmology, Immunology, Other Applications 3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Government Research Institutes, Contract Research Organizations (CROs) Subsegments: 1) By Clinical Trial Design And Planning: Protocol Development, Feasibility Studies, Patient Recruitment Strategy Design 2) By Supply And Logistics Services: Cold Chain Management, Investigational Product Packaging And Labeling, Controlled-Temperature Storage 3) By Regulatory Services: Regulatory Consulting And Strategy, Ethics Committee Submissions, Regulatory Compliance Monitoring 4) By Data Management And Biostatistics: Clinical Data Capture And Database Design, Data Validation And Quality Control, Statistical Analysis And Modeling 5) By Site Management And Monitoring: Site Selection And Qualification, Investigator Training And Support, On-Site Monitoring Visits 6) By Other Types: Pharmacovigilance And Safety Reporting, Quality Assurance And Auditing, Patient Engagement And Retention

What Is The Driver Of The Gene Therapy Clinical Trial Services Market?

The increasing demand for personalized medicine is expected to propel the growth of the gene therapy clinical trial services market going forward. Personalized medicine is an approach that tailors medical treatment to individual characteristics, such as genetic, biomarker, and lifestyle factors. The personalized medicine demand is rising due to advancements in genomics and biotechnology, which enable more precise targeting of therapies. Gene therapy clinical trial services support personalized medicine by analyzing patient-specific genetic profiles and customizing treatments accordingly, using biomarker analysis and companion diagnostics to optimize therapy for each individual while enhancing safety and effectiveness. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the gene therapy clinical trial services industry.

Key Players In The Global Gene Therapy Clinical Trial Services Market

Major companies operating in the gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, Labcorp, Pharmaceutical Product Development LLC, ICON plc, Syneos Health Inc., WuXi AppTec, Franklin Biolabs, Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Medpace Holdings Inc., Precision Medicine Group LLC, Worldwide Clinical Trials, IQVIA Holdings Inc., TFS HealthScience, Veristat LLC, Novotech Health Holdings Pte Limited, Covance Inc., PPD Clinical Research Services, PRA Health Sciences Inc.

Global Gene Therapy Clinical Trial Services Market Trends and Insights

Major companies operating in the gene therapy clinical trial services market are focusing on developing innovative solutions such as long-term follow-up (LTFU) model for cell and gene therapy (CGT) trials to accelerate the overall trial process while maintaining regulatory compliance and safety standards. A Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials is a structured framework designed to monitor patients over an extended period, often up to 15 years after receiving a CGT treatment. For instance, in May 2025, Medable Inc., a US-based SaaS company, launched a digital-first Long-Term Follow-Up (LTFU) model specifically designed for cell and gene therapy (CGT) trials. It supports cell and gene therapy trials by reducing patient and site burdens while ensuring scientific rigor over the FDA-required 15-year monitoring period. It improves patient access, retention, and data continuity through remote and hybrid follow-up methods, enhancing long-term safety and efficacy monitoring.

What Are Latest Mergers And Acquisitions In The Gene Therapy Clinical Trial Services Market?

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc for an undisclosed amount. Through this acquisition, Kyowa Kirin aims to enhance its gene therapy capabilities and expand its presence in the advanced therapies industry, particularly focusing on rare diseases and genetic disorders. Orchard Therapeutics plc is a UK-based biotechnology company that offers gene therapy clinical trial services.

Regional Outlook

North America was the largest region in the gene therapy clinical trial services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gene Therapy Clinical Trial Services Market?

The gene therapy clinical trial services market includes revenues earned by entities by providing services such as patient recruitment and enrollment, clinical trial site selection and setup, pharmacovigilance and safety monitoring, biomarker analysis and companion diagnostics, and training and support for clinical staff. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gene Therapy Clinical Trial Services Market Report 2026?

The gene therapy clinical trial services market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy clinical trial services industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.